Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-08-07
2007-08-07
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252140, C514S252170, C514S254110, C514S254040, C514S253010, C514S254090, C544S373000, C544S360000, C544S295000, C544S374000, C544S377000, C544S368000
Reexamination Certificate
active
10481359
ABSTRACT:
Compounds having Formula I, including pharmaceutically acceptable salts and prodrugs thereof: (I) are inhibitors of the dipeptidyl peptidase-IV enzyme (DP-IV), and are useful in the treatment of DP-IV mediated diseases and conditions, such as non-insulin dependent diabetes mellitus
REFERENCES:
patent: 4386090 (1983-05-01), Moinet et al.
patent: 5939560 (1999-08-01), Jenkins et al.
patent: WO 9719908 (1997-06-01), None
patent: WO 97/40832 (1997-11-01), None
patent: WO 98/19998 (1998-05-01), None
patent: WO 98/19998 (1998-05-01), None
patent: WO 9856771 (1998-12-01), None
patent: WO 00/34241 (2000-06-01), None
patent: WO 01/34594 (2001-05-01), None
patent: WO 01/96295 (2001-12-01), None
patent: WO 01/96295 (2001-12-01), None
patent: WO 02/02560 (2002-01-01), None
patent: WO 02/02560 (2002-01-01), None
patent: WO 02/076450 (2002-10-01), None
patent: WO 03/000180 (2003-01-01), None
patent: WO 03/000180 (2003-01-01), None
patent: WO 03/000181 (2003-01-01), None
patent: WO 03/000181 (2003-01-01), None
patent: WO 03/004498 (2003-01-01), None
patent: WO 03/082817 (2003-10-01), None
Deacon et al. Expert Opin. Investig. Drugs (2004) 13(9): 1091-1102.
Expert Opinion onTherapeutic Patents, “Novel N-substituted-2-cyanopyrrolidines as potent inhibitors of dipeptidyl peptidase IV in the treatment of non-insulin-dependent diabetes mellitus”, vol. 10 (#12) p. 1937-1942 (2000).
Expert Opinion on Investig. Drugs, “Gut peptides in the treatment of diabetes mellitus”, (2004) 13 (3) 177-188.
Expert Opinion on Investig. Drugs, “Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes”, (2003) 12: 87-100.
Expert Opinion on Therapeutic Patents, “Dipeptidyl peptidase IV inhibitors as new therapeutic agents for the treatment of Type 2 diabetes”, (2003) 13: 499-510.
Brockunier Linda
Parmee Emma
Weber Ann E.
Anderson Rebecca
Durette Philippe L.
Fitch Catherine D.
Merck & Co. , Inc.
LandOfFree
Dipeptidyl peptidase inhibitors for the treatment of diabetes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dipeptidyl peptidase inhibitors for the treatment of diabetes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dipeptidyl peptidase inhibitors for the treatment of diabetes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3885214